Scheme 6.
Synthesis (A) and anticancer evaluation (B) of thiazolidine-2,4-dione hybrids developed by Eissa’s group. (HepG2: hepatic carcinoma cells; HCT-116, HT-29 and Caco-2: colon cancer cells; MCF-7 and MDA-MB-231: breast cancer cells; A549: lung cancer cells; VERO: normal kidney cells; Sor: sorafenib; Dox: doxorubicin).
